Business Description
Vistagen Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92840H2022
Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 54.39 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.81 | |||||
| Beneish M-Score | -2.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -47.5 | |||||
| 3-Year EBITDA Growth Rate | 34.9 | |||||
| 3-Year EPS without NRI Growth Rate | 53.1 | |||||
| 3-Year FCF Growth Rate | 32.3 | |||||
| 3-Year Book Growth Rate | -34.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -9.75 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.21 | |||||
| 9-Day RSI | 44.11 | |||||
| 14-Day RSI | 42.03 | |||||
| 6-1 Month Momentum % | -26.23 | |||||
| 12-1 Month Momentum % | -19.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.29 | |||||
| Quick Ratio | 13.29 | |||||
| Cash Ratio | 12.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -65 | |||||
| Shareholder Yield % | -127.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -5211.54 | |||||
| Net Margin % | -4521.71 | |||||
| FCF Margin % | -3838.86 | |||||
| ROE % | -42 | |||||
| ROA % | -38.57 | |||||
| ROIC % | -852.87 | |||||
| ROC (Joel Greenblatt) % | -2006.2 | |||||
| ROCE % | -46.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 89.33 | |||||
| PB Ratio | 0.78 | |||||
| Price-to-Tangible-Book | 0.78 | |||||
| EV-to-EBIT | 0.51 | |||||
| EV-to-EBITDA | 0.52 | |||||
| EV-to-Revenue | -26.73 | |||||
| EV-to-Forward-Revenue | 137.87 | |||||
| EV-to-FCF | 0.7 | |||||
| Price-to-Net-Current-Asset-Value | 0.81 | |||||
| Price-to-Net-Cash | 0.83 | |||||
| Earnings Yield (Greenblatt) % | 196.08 | |||||
| FCF Yield % | -44.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VTGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vistagen Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.875 | ||
| EPS (TTM) ($) | -1.342 | ||
| Beta | 0.19 | ||
| Volatility % | 56.27 | ||
| 14-Day RSI | 42.03 | ||
| 14-Day ATR ($) | 0.150226 | ||
| 20-Day SMA ($) | 2.85525 | ||
| 12-1 Month Momentum % | -19.95 | ||
| 52-Week Range ($) | 2.48 - 5.86 | ||
| Shares Outstanding (Mil) | 27.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vistagen Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vistagen Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vistagen Therapeutics Inc Frequently Asked Questions
What is Vistagen Therapeutics Inc(VTGN)'s stock price today?
The current price of VTGN is $2.69. The 52 week high of VTGN is $5.86 and 52 week low is $2.48.
When is next earnings date of Vistagen Therapeutics Inc(VTGN)?
The next earnings date of Vistagen Therapeutics Inc(VTGN) is 2025-02-13 Est..
Does Vistagen Therapeutics Inc(VTGN) pay dividends? If so, how much?
Vistagen Therapeutics Inc(VTGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers